Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
Website:
http://www.contineum-tx.comNext earnings report:
30 August 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Fri, 05 Jul 2024 21:01:41 GMTDividend
Analysts recommendations
Institutional Ownership
CTNM Latest News
SAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (Nasdaq: CTNM), a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that target biological pathways associated with specific clinical impairments for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced that Company management will participate in the 45th Annual Goldman Sachs Healthcare Conference, taking place June 10-13, 2024.
U.S. IPO Weekly Recap: April IPO Market Gets A Boost From Large Launches And New Filings
Contineum Therapeutics (NASDAQ:CTNM) stock is a hot topic among traders on Friday as they prepare for the clinical-stage biopharmaceutical company's shares to go public today. Let's go over everything traders need to know about Contineum Therapeutics ahead of its initial public offering ( IPO ) later today!
What type of business is Contineum Therapeutics Class A Common Stock?
Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). The company also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor to treat depression and relapse remitting MS; and CTX-343, a peripherally-restricted LPA1R antagonist. Contineum Therapeutics, Inc. was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. The company was incorporated in 2009 and is headquartered in San Diego, California.
What sector is Contineum Therapeutics Class A Common Stock in?
Contineum Therapeutics Class A Common Stock is in the Healthcare sector
What industry is Contineum Therapeutics Class A Common Stock in?
Contineum Therapeutics Class A Common Stock is in the Biotechnology industry
What country is Contineum Therapeutics Class A Common Stock from?
Contineum Therapeutics Class A Common Stock is headquartered in United States
What is Contineum Therapeutics Class A Common Stock website?
https://www.contineum-tx.com
Is Contineum Therapeutics Class A Common Stock in the S&P 500?
No, Contineum Therapeutics Class A Common Stock is not included in the S&P 500 index
Is Contineum Therapeutics Class A Common Stock in the NASDAQ 100?
No, Contineum Therapeutics Class A Common Stock is not included in the NASDAQ 100 index
Is Contineum Therapeutics Class A Common Stock in the Dow Jones?
No, Contineum Therapeutics Class A Common Stock is not included in the Dow Jones index
When does Contineum Therapeutics Class A Common Stock report earnings?
The next expected earnings date for Contineum Therapeutics Class A Common Stock is 30 August 2024